Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia

Current Alzheimer Research

Volumn 10, Issue 6, 2013, Pages 642-653

  Akinyemi, Rufus O ^a   Mukaetova Ladinska, Elizabeta B ^a   Attems, Johannes ^a   Ihara, Masafumi ^b   Kalaria, Raj N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Ageing; Alzheimer's disease; Cerebral blood flow; Dementia; Diabetes; Diet; Physical actvity; Stroke; Vascular dementia; White matter lesions

Indexed keywords

ALCOHOL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

AGING; ALLELE; ALZHEIMER DISEASE; AUTOREGULATION; BLOOD BRAIN BARRIER; BRAIN; BRAIN ATROPHY; CEREBROVASCULAR DISEASE; COGNITION; DIABETES MELLITUS; DIET; DISEASE MARKER; DYSLIPIDEMIA; EXERCISE; HEREDITY; HUMAN; HYPERTENSION; LIFESTYLE; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROIMAGING; NUTRITION; OBESITY; OXIDATIVE STRESS; PERFUSION; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; RISK FACTOR; VASCULAR DISEASE; WHITE MATTER;

AGING; ALZHEIMER DISEASE; ANIMALS; DEMENTIA, VASCULAR; HUMANS; NERVE DEGENERATION; RISK FACTORS; VASCULAR DISEASES;

EID: 84882801362     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113109990037     Document Type: Review

References (156)

1. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349(9046): 151-4 (1997).
2. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57(6): 789-94 (2005).
3. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42(9): 2672-713 (2011).
4. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology 72(4): 368-74 (2009).
5. Kalaria RN. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 203-20429-34 (2002).
6. Roman G. Vascular dementia: a historical background. Int Psychogeriatr 15(1): 111-3 (2003).
7. Berrios GE, Freeman HL. Alzheimer and the dementiaa. In: Berrios GE, editor. Eponymists in Medicine Series. London: Royal Society of Medicine Services; 1991. p. 69-76.
8. Erkinjuntti T, Kalaria R. Vascular Cognitive Impairment. In: Growdon J, Rossor M, editors. The Dementias: Elsevier; 2006.
9. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 11(3): 205-42 (1970).
10. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci 7(2): 331-56 (1968).
11. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 2(7874): 207-10 (1974).
12. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43(2): 250-60 (1993).
13. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37(9): 2220-41 (2006).
14. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 121(4): 505-11 (2010).
15. Ogata J, Yamanishi H, Ishibashi-Ueda H. Review: role of cerebral vessels in ischaemic injury of the brain. Neuropathol Appl Neurobiol 37(1): 40-55 (2011).
16. Ferrer I, Kaste M, Kalimo H. Vascular diseases. In: Love S, Louis D, Ellison D, editors. Greenfield's Neuropathology. 8th ed. Oxford: Oxford University Press; 2008. p. 121-240.
17. Kalaria RN. Cerebral vessels in ageing and Alzheimer's disease. Pharmacol Ther 72(3): 193-214 (1996).
18. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 100(1): 328-35 (2006).
19. Kalaria RN. Linking cerebrovascular defense mechanisms in brain ageing and Alzheimer's disease. Neurobiol Aging 30(9): 1512-4 (2009).
20. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5(5): 347-60 (2004).
21. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci 10(11): 1369-76 (2007).
22. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33(4): 1152-62 (2002).
23. Lewis H, Beher D, Cookson N, Oakley A, Piggott M, Morris CM, et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 32(2): 103-18 (2006).
24. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277(10): 813-7 (1997).
25. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 21(2): 321-30 (2000).
26. Kalaria RN. Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol 5(6): 305-6 (2009).
27. Yamamoto Y, Ihara M, Tham C, Low RW, Slade JY, Moss T, et al. Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke 40(6): 2004-11 (2009).
28. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloidbeta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8(1): 16-30 (2009).
29. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106(12): 1489-99 (2000).
30. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13(9): 1029-31 (2007).
31. Klann E, Dever TE. Biochemical mechanisms for translational regulation in synaptic plasticity. Nat Rev Neurosci 5(12): 931-42 (2004).
32. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 27(12): 1769-85 (2006).
33. Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal deficits in CADASIL. Stroke 38(1): 188-91 (2007).
34. Faraci FM. Reactive oxygen species: influence on cerebral vascular tone. J Appl Physiol 100(2): 739-43 (2006).
35. Miller AA, Drummond GR, Schmidt HH, Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 97(10): 1055-62 (2005).
36. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87(1): 315-424 (2007).
37. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol 27(2): 303-9 (2007).
38. Bennett S, Grant MM, Aldred S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J Alzheimers Dis 17(2): 245-57 (2009).
39. Massaad CA, Amin SK, Hu L, Mei Y, Klann E, Pautler RG. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. PLoS One 5(5): e10561 (2010).
40. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10(9): 785-96 (2011).
41. Knopman DS. Cerebrovascular disease and dementia. Br J Radiol 80 Spec No 2S121-7 (2007).
42. Mills S, Cain J, Purandare N, Jackson A. Biomarkers of cerebrovascular disease in dementia. Br J Radiol 80 Spec No 2S128-45 (2007).
43. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. Neurology 71(11): 804-11 (2008).
44. Zimmerman ME, Pan JW, Hetherington HP, Katz MJ, Verghese J, Buschke H, et al. Hippocampal neurochemistry, neuromorphometry, and verbal memory in nondemented older adults. Neurology 70(18): 1594-600 (2008).
45. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al. Changes in white matter as determinant of global functional decline in older independent outpatients: three year followup of LADIS (leukoaraiosis and disability) study cohort. BMJ 339 b2477 (2009).
46. Polvikoski TM, van Straaten EC, Barkhof F, Sulkava R, Aronen HJ, Niinisto L, et al. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 75(23): 2071-8 (2010).
47. Ihara M, Polvikoski TM, Hall R, Slade JY, Perry RH, Oakley AE, et al. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol 119(5): 579-89 (2010).
48. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, et al. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke 37(6): 1391-8 (2006).
49. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging 30(3): 337-52 (2009).
50. Yamaji S, Ishii K, Sasaki M, Imamura T, Kitagaki H, Sakamoto S, et al. Changes in cerebral blood flow and oxygen metabolism related to magnetic resonance imaging white matter hyperintensities in Alzheimer's disease. J Nucl Med 38(9): 1471-4 (1997).
51. Takahashi W, Takagi S, Ide M, Shohtsu A, Shinohara Y. Reduced cerebral glucose metabolism in subjects with incidental hyperintensities on magnetic resonance imaging. J Neurol Sci 176(1): 21-7 (2000).
52. Derouesne C, Poirier J. [Cerebral lacunae: still under debate]. Rev Neurol (Paris) 155(10): 823-31 (1999).
53. Ogawa T, Okudera T, Fukasawa H, Hashimoto M, Inugami A, Fujita H, et al. Unusual widening of Virchow-Robin spaces: MR appearance. AJNR Am J Neuroradiol 16(6): 1238-42 (1995).
54. Alzheimer A. Uber eine eigenartig Erkrankung er Hirnrinde. Allg Z Psychaitr Psych-Gerichtl Med 64146-48 (1907).
55. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13 Suppl 3 S115-23 (1999).
56. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 19(3): 253-62 (1986).
57. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 148(6): 2083-95 (1996).
58. Riekse RG, Leverenz JB, McCormick W, Bowen JD, Teri L, Nochlin D, et al. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. J Am Geriatr Soc 52(9): 1442-8 (2004).
59. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci 226(1-2): 75-80 (2004).
60. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4(8): 487-99 (2005).
61. Firbank MJ, Burton EJ, Barber R, Stephens S, Kenny RA, Ballard C, et al. Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiol Aging 28(11): 1664-9 (2007).
62. Firbank MJ, He J, Blamire AM, Singh B, Danson P, Kalaria RN, et al. Cerebral blood flow by arterial spin labeling in poststroke dementia. Neurology 76(17): 1478-84 (2011).
63. Gemmell E, Bosomworth H, Allan L, Hall R, Khundakar A, Oakley AE, et al. Hippocampal Neuronal Atrophy and Cognitive Function in Delayed Poststroke and Aging-Related Dementias. Stroke (2011).
64. Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y, et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 41(6): 1278-84 (2010).
65. Seshadri S. Methodology for measuring cerebrovascular disease burden. Int Rev Psychiatry 18(5): 409-22 (2006).
66. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res Rev 8(2): 61-70 (2009).
67. Knopman DS. Hypertension and late-life dementia: A real link? Neurology 72(20): 1716-7 (2009).
68. Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive function in healthy old people. J Am Geriatr Soc 41(7): 753-6 (1993).
69. Seux ML, Thijs L, Forette F, Staessen JA, Birkenhager WH, Bulpitt CJ, et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 16(7): 963-9 (1998).
70. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347(9009): 1141-5 (1996).
71. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322(7300): 1447-51 (2001).
72. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al. Cardiovascular risk factors and cognitive decline in middleaged adults. Neurology 56(1): 42-8 (2001).
73. Bohannon AD, Fillenbaum GG, Pieper CF, Hanlon JT, Blazer DG. Relationship of race/ethnicity and blood pressure to change in cognitive function. J Am Geriatr Soc 50(3): 424-9 (2002).
74. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology 61(12): 1667-72 (2003).
75. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA, Evans DA. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 58(10): 1640-6 (2001).
76. Sharp SI, Aarsland D, Day S, Sonnesyn H, Ballard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry (2011).
77. Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 68 Suppl 2 S74-87 (2010).
78. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. Angiotensin receptor blocker prevented beta-amyloid induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54(6): 1345-52 (2009).
79. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev (2): CD004034 (2006).
80. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology 72(20): 1727-34 (2009).
81. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman HT, et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72(20): 1720-6 (2009).
82. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev (4): CD004034 (2009).
83. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ, Kessels RP. The effects of type 1 diabetes on cognitive performance: a metaanalysis. Diabetes Care 28(3): 726-35 (2005).
84. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 75(13): 1195-202 (2010).
85. Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis 16(4): 677-85 (2009).
86. Murthy SB, Jawaid A, Qureshi SU, Kalkonde Y, Wilson AM, Johnson ML, et al. Does diabetes mellitus alter the onset and clinical course of vascular dementia? Behav Neurol 23(3): 145-51 (2010).
87. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16(4): 693-704 (2009).
88. Reynolds RM, Strachan MW, Labad J, Lee AJ, Frier BM, Fowkes FG, et al. Morning cortisol levels and cognitive abilities in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 33(4): 714-20 (2010).
89. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 38(9): 1096-102 (1995).
90. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 20(10): 2255-60 (2000).
91. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315(7115): 1045-9 (1997).
92. Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res 59267-85 (2004).
93. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Jr., Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330(7504): 1360 (2005).
94. Whitmer RA. The epidemiology of adiposity and dementia. Curr Alzheimer Res 4(2): 117-22 (2007).
95. Hughes TF, Borenstein AR, Schofield E, Wu Y, Larson EB. Association between late-life body mass index and dementia: The Kame Project. Neurology 72(20): 1741-6 (2009).
96. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17(1): 14-20 (1998).
97. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137(3): 149-55 (2002).
98. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28(1): 75-80 (2009).
99. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 163(9): 1053-7 (2003).
100. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61(5): 705-14 (2004).
101. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, et al. Lipid metabolism in cognitive decline and dementia. Brain Res Rev 51(2): 275-92 (2006).
102. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98(10): 5856-61 (2001).
103. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346): 1623-30 (2002).
104. HPSCGroup. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326): 7-22 (2002).
105. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev (2): CD003160 (2009).
106. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev (8): CD007514 (2010).
107. Muangpaisan W, Brayne C. Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr Gerontol Int 10(2): 199-208 (2010).
108. Howard G, Wagenknecht LE, Cai J, Cooper L, Kraut MA, Toole JF. Cigarette smoking and other risk factors for silent cerebral infarction in the general population. Stroke 29(5): 913-7 (1998).
109. Armani C, Landini L, Jr., Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr Pharm Des 15(10): 1038-53 (2009).
110. Tyas SL, White LR, Petrovitch H, Webster Ross G, Foley DJ, Heimovitz HK, et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 24(4): 589-96 (2003).
111. Rusanen M, Rovio S, Ngandu T, Nissinen A, Tuomilehto J, Soininen H, et al. Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based cardiovascular risk factors, aging and dementia study. Dement Geriatr Cogn Disord 30(3): 277-84 (2010).
112. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol 61(5): 403-10 (2007).
113. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 53(7): 1101-7 (2005).
114. Zuccala G, Onder G, Marzetti E, Monaco MR, Cesari M, Cocchi A, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 26(3): 226-33 (2005).
115. Pullicino PM, Hart J. Cognitive impairment in congestive heart failure?: Embolism vs hypoperfusion. Neurology 57(11): 1945-6 (2001).
116. Seshadri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis 9(4): 393-8 (2006).
117. Zylberstein DE, Lissner L, Bjorkelund C, Mehlig K, Thelle DS, Gustafson D, et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging (2009).
118. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 4(2): 363-81 (2008).
119. Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 67(1): 93-8 (2010).
120. Barberger-Gateau P, Samieri C, Feart C, Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res 8(5): 479-91 (2011).
121. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2): 178-201 (2008).
122. Zlokovic BV. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5(3): 409-14 (2008).
123. Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D'Onofrio G, et al. Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res 8(5): 520-42 (2011).
124. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337 a1344 (2008).
125. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 63(12): 1709-17 (2006).
126. Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer's disease. Curr Neurol Neurosci Rep 7(5): 366-72 (2007).
127. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60(7): 940-6 (2003).
128. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85(4): 1142-7 (2007).
129. Kidd PM. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 13(2): 85-115 (2008).
130. Crichton GE, Bryan J, Murphy KJ, Buckley J. Review of dairy consumption and cognitive performance in adults: findings and methodological issues. Dement Geriatr Cogn Disord 30(4): 352-61 (2010).
131. Krikorian R, Nash TA, Shidler MD, Shukitt-Hale B, Joseph JA. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr 103(5): 730-4 (2010).
132. Craggs L, Kalaria RN. Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport (2010).
133. Joseph JA, Shukitt-Hale B, Willis LM. Grape juice, berries, and walnuts affect brain aging and behavior. J Nutr 139(9): 1813S-7S (2009).
134. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61(1): 82-8 (2004).
135. Markus MA, Morris BJ. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 3(2): 331-9 (2008).
136. Mandel SA, Amit T, Weinreb O, Youdim MB. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis 25(2): 187-208 (2011).
137. Marques FZ, Markus MA, Morris BJ. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 41(11): 2125-8 (2009).
138. Dishman RK, Berthoud HR, Booth FW, Cotman CW, Edgerton VR, Fleshner MR, et al. Neurobiology of exercise. Obesity (Silver Spring) 14(3): 345-56 (2006).
139. Driver HS, Taylor SR. Exercise and sleep. Sleep Med Rev 4(4): 387-402 (2000).
140. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: efficacy and dose response. Am J Prev Med 28(1): 1-8 (2005).
141. van Gelder BM, Tijhuis MA, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D. Physical activity in relation to cognitive decline in elderly men: the FINE Study. Neurology 63(12): 2316-21 (2004).
142. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 302(6): 627-37 (2009).
143. Rovio S, Spulber G, Nieminen LJ, Niskanen E, Winblad B, Tuomilehto J, et al. The effect of midlife physical activity on structural brain changes in the elderly. Neurobiol Aging (2008).
144. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300(9): 1027-37 (2008).
145. Aarsland D, Sardahaee FS, Anderssen S, Ballard C. Is physical activity a potential preventive factor for vascular dementia? A systematic review. Aging Ment Health 14(4): 386-95 (2010).
146. Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E, et al. Aerobic exercise training increases brain volume in aging humans. J Gerontol A Biol Sci Med Sci 61(11): 1166-70 (2006).
147. Neeper SA, Gomez-Pinilla F, Choi J, Cotman CW. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 726(1-2): 49-56 (1996).
148. Ang ET, Wong PT, Moochhala S, Ng YK. Neuroprotection associated with running: is it a result of increased endogenous neurotrophic factors? Neuroscience 118(2): 335-45 (2003).
149. Tong L, Shen H, Perreau VM, Balazs R, Cotman CW. Effects of exercise on gene-expression profile in the rat hippocampus. Neurobiol Dis 8(6): 1046-56 (2001).
150. Li J, Luan X, Clark JC, Rafols JA, Ding Y. Neuroprotection against transient cerebral ischemia by exercise pre-conditioning in rats. Neurol Res 26(4): 404-8 (2004).
151. Ding Y, Li J, Luan X, Ding YH, Lai Q, Rafols JA, et al. Exercise pre-conditioning reduces brain damage in ischemic rats that may be associated with regional angiogenesis and cellular overexpression of neurotrophin. Neuroscience 124(3): 583-91 (2004).
152. Lee MH, Kim H, Kim SS, Lee TH, Lim BV, Chang HK, et al. Treadmill exercise suppresses ischemia-induced increment in apoptosis and cell proliferation in hippocampal dentate gyrus of gerbils. Life Sci 73(19): 2455-65 (2003).
153. Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Asada M, et al. Environmental enrichment ameliorated high-fat diet-induced Abeta deposition and memory deficit in APP transgenic mice. Neurobiol Aging (2011).
154. Baker LD, Bayer-Carter JL, Skinner J, Montine TJ, Cholerton BA, Callaghan M, et al. High-Intensity Physical Activity Modulates Diet Effects on Cerebrospinal Amyloid-beta Levels in Normal Aging and Mild Cognitive Impairment. J Alzheimers Dis (2011).
155. Kitaguchi H, Tomimoto H, Ihara M, Shibata M, Uemura K, Kalaria RN, et al. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res 19 (1294): 202-10 (2009)
156. Gelber RP, Petrovitch H, Masaki KH, Abbott RD, Ross GW, Launer LJ, et al. Lifestyle and the risk of dementia in Japaneseamerican men. J Am Geriatr Soc 60(1): 118-23 (2012).